title: Antibody-drug conjugates.
authors.forename: Rachel S
authors.initials: RS
authors.lastname: Zolot
authors.forename: Satarupa
authors.initials: S
authors.lastname: Basu
authors.forename: Ryan P
authors.initials: RP
authors.lastname: Million
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000627:therapeutic use*; D008453:Maytansine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D013678:Technology, Pharmaceutical / Q000379:methods; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine
references.citation: Nat Rev Drug Discov. 2010 Sep;9(9):665-7
references.pmid: 20811367